drugset / Trial / NCT02954796
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study tests the safety of a drug called SGN-CD352A, to find out what its side effects are. SGN-CD352A will be given every 4 weeks to a small group of patients with multiple myeloma.
Timeline
- Start
- 2016-12
- Primary completion
- 2019-07-17
- Completion
- 2019-07-17
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision based on portfolio prioritization”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SGN-CD352A | Unknown | 4 ug/kg | Intravenous |
| Subject | SGN-CD352A | Unknown | 65 ug/kg | Intravenous |